Cardio Diagnostics (NASDAQ:CDIO) Stock Price Down 5.7%

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) shares fell 5.7% on Thursday . The stock traded as low as $1.00 and last traded at $1.00. 1,620,059 shares changed hands during mid-day trading, a decline of 60% from the average session volume of 4,001,855 shares. The stock had previously closed at $1.06.

Cardio Diagnostics Price Performance

The company’s 50-day simple moving average is $0.46 and its two-hundred day simple moving average is $0.95.

Institutional Trading of Cardio Diagnostics

Several institutional investors and hedge funds have recently modified their holdings of CDIO. Bank of America Corp DE bought a new stake in Cardio Diagnostics in the 1st quarter valued at $59,000. Prelude Capital Management LLC bought a new stake in Cardio Diagnostics in the 2nd quarter valued at $131,000. State Street Corp bought a new stake in Cardio Diagnostics in the 1st quarter valued at $163,000. Finally, Geode Capital Management LLC bought a new stake in Cardio Diagnostics in the 1st quarter valued at $290,000. 3.46% of the stock is currently owned by institutional investors.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.